Skip to main content
NewslettersWatchlist

Atea Pharmaceuticals Inc(AVIR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference

Globe NewsWire - Wed Sep 29, 2021

BOSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on Tuesday, October 5, 2021 at 9:30 a.m. ET.

A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com


Primary Logo

Provided Content: Content provided by Globe NewsWire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

investor newsletter
A look at how people are using the best all-around investing product. Plus, top stock picks from our new Readers’ Portfolio
ETF or Exchange Traded Fund text on black block
market news
The close: Month-end repositioning spurs late-day stock rally
Trader Anthony Confusione works on the floor of the New York Stock Exchange, Thursday, May 30.
alternative investments
Why this money manager thinks investors should get off the sidelines but still be defensive
Illustration of Chris Kerlow for The Mover. June 23/24, 2023. Illustration by Joel Kimmel
globe advisor weekly newsletter
Canadian investors are ‘underserved’ in alternative investments and private capital
Investors want greater clarity from their advisors around what RI means and how it can fit their portfolios.
alternative investments
Why rising interest in traditional fixed income is not affecting alternatives
A man looks up as he leans a red ladder against a tall stack of coins that is topped with an interest rate symbol.
alternative investments
Fund houses buy up ‘alts’ specialists to move beyond equities and bonds
FILE PHOTO: Larry Fink, Chief Executive Officer of BlackRock, takes part in the Yahoo Finance All Markets Summit in New York, U.S., February 8, 2017. REUTERS/Lucas Jackson
opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza
alternative investments
Four ways to create more diversified and resilient portfolios
One of a set. Graphic Arrow on abstract background.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).